Compile Data Set for Download or QSAR
Report error Found 54 Enz. Inhib. hit(s) with all data for entry = 11966
TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665958(US20240116926, Example 45)
Affinity DataIC50: 12nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665956(US20240116926, Example 43)
Affinity DataIC50: 12nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665952(US20240116926, Example 39)
Affinity DataIC50: 13nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665957(US20240116926, Example 44)
Affinity DataIC50: 16nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665947(US20240116926, Example 34)
Affinity DataIC50: 17nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665922(US20240116926, Example 9)
Affinity DataIC50: 21nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665937(US20240116926, Example 24)
Affinity DataIC50: 23nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665928(US20240116926, Example 15)
Affinity DataIC50: 25nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665933(US20240116926, Example 20)
Affinity DataIC50: 25nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665961(US20240116926, Example 48)
Affinity DataIC50: 26nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665932(US20240116926, Example 19)
Affinity DataIC50: 26nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665918(US20240116926, Example 5)
Affinity DataIC50: 27nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665940(US20240116926, Example 27)
Affinity DataIC50: 29nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665963(US20240116926, Example 50)
Affinity DataIC50: 30nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665965(US20240116926, Comparative Example B | 1-[3-({2-[4...)
Affinity DataIC50: 30nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665923(US20240116926, Example 10)
Affinity DataIC50: 32nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665920(US20240116926, Example 7)
Affinity DataIC50: 33nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665924(US20240116926, Example 11)
Affinity DataIC50: 33nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665926(US20240116926, Example 13)
Affinity DataIC50: 41nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665936(US20240116926, Example 23)
Affinity DataIC50: 42nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665945(US20240116926, Example 32 | 1-((3S,4R)-3-hydroxy-4...)
Affinity DataIC50: 42nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665934(US20240116926, Example 21)
Affinity DataIC50: 42nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665960(US20240116926, Example 47)
Affinity DataIC50: 42nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665927(US20240116926, Example 14)
Affinity DataIC50: 49nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665949(US20240116926, Example 36)
Affinity DataIC50: 51nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665925(US20240116926, Example 12)
Affinity DataIC50: 52nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665966(US20240116926, Comparative Example C | 1-(3-{4-[4-...)
Affinity DataIC50: 55nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665921(US20240116926, Example 8)
Affinity DataIC50: 56nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665915(US20240116926, Example 2)
Affinity DataIC50: 56nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665938(US20240116926, Example 25)
Affinity DataIC50: 57nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665962(US20240116926, Example 49)
Affinity DataIC50: 59nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665941(US20240116926, Example 28)
Affinity DataIC50: 61nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665930(US20240116926, Example 17)
Affinity DataIC50: 61nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665951(US20240116926, Example 38)
Affinity DataIC50: 64nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665946(US20240116926, Example 33)
Affinity DataIC50: 68nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665955(US20240116926, Example 42)
Affinity DataIC50: 70nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665954(US20240116926, Example 41)
Affinity DataIC50: 72nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665944(US20240116926, Example 31)
Affinity DataIC50: 73nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665939(US20240116926, Example 26)
Affinity DataIC50: 76nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665919(US20240116926, Example 6)
Affinity DataIC50: 78nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665948(US20240116926, Example 35)
Affinity DataIC50: 79nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665914(US20240116926, Example 1)
Affinity DataIC50: 93nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665916(US20240116926, Example 3 | US20240116926, Example ...)
Affinity DataIC50: 93nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665943(US20240116926, Example 30 | trans-1-acryloyl-4-((4...)
Affinity DataIC50: 100nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665942(US20240116926, Example 29)
Affinity DataIC50: 130nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665950(US20240116926, Example 37)
Affinity DataIC50: 180nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665931(US20240116926, Example 18)
Affinity DataIC50: 200nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665953(US20240116926, Example 40)
Affinity DataIC50: 250nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665929(US20240116926, Example 16)
Affinity DataIC50: 270nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTranscriptional enhancer factor TEF-3 [217-434](Human)
Astrazeneca

US Patent
LigandPNGBDBM665916(US20240116926, Example 3 | US20240116926, Example ...)
Affinity DataIC50: 410nMAssay Description:Compound IC50 values were assessed following a 10-point, half-log10 dilution schema starting at 100 μM compound concentration. Specifically, hum...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 54 total ) | Next | Last >>
Jump to: